Andere talen Cellectar Biosciences, Inc.

Aandelen

CLRB

US15117F8077

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,07 ^USD	-5,25%		-10,23%	+10,83%

28/03	CELLECTAR BIOSCIENCES, INC. : Roth MKM handhaaft koopadvies	ZM
28/03	CELLECTAR BIOSCIENCES, INC. : Oppenheimer handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03
Cellectar Biosciences : Corporate Presentation - March 2024	18/03
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30/01
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25/01
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23/01
Sector Update: Health Care Stocks Advance Late Afternoon	22/01
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	22/01
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	22/01
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	22/01
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	17/01
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data	16/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cellectar Biosciences, Inc.

Aandelen

CLRB

US15117F8077

Andere talen

Filters